Prognostic Significance of Simvastatin Therapy in
Patients With Ischemic Heart Failure Who Underwent
Percutaneous Coronary Intervention for Acute
Myocardial Infarction
- Author(s)
- Young Joon Hong; Myung Ho Jeong; Dae Woo Hyun; Seung Ho Hur; Kwon Bae Kim; Weon Kim; Sang Yup Lim; Sang Hyun Lee; Seo Na Hong; Dong Goo Kang; Kyung Ho Yun; Kye Hun Kim; Yun Sang Lee; Hyung Wook Park; Ju Han Kim; Young Keun Ahn; Jeong Gwan Cho; Jong Chun Park; Jung Chaee Kang
- Keimyung Author(s)
- Hur, Seung Ho; Kim, Kwon Bae
- Department
- Dept. of Internal Medicine (내과학)
- Journal Title
- American Journal of Cardiology
- Issued Date
- 2005
- Volume
- 95
- Issue
- 5
- Abstract
- We prospectively followed 202 patients with ischemic heart failure who underwent percutaneous coronary intervention (PCI) for acute myocardial infarction (left ventricular [LV] ejection fraction <40%). Patients were divided into 2 groups: groups I (simvastatin group, n106, aged 60.8 10.3 years, men 71.7%) and II (non-simvastatin group, n 96, aged 60.9 10.4 years, men 78.1%). During 1-year clinical follow-up, simvastatin therapy was associated with a significant reduction in mortality (1.9% vs 7.5%, p 0.048), restenosis rate (25.7% vs 43.1%, p 0.033), and repeat PCI rate (25.7% vs 43.1%, p 0.033), and with significant improvement in LV ejection fraction (31% to 42% vs 32% to 39%, p 0.042). The event-free survival rate was higher in group I than in group II (79.8% vs 57.0%, p 0.001). In conclusion, simvastatin therapy improves LV systolic function and decreases mortality, restenosis, and repeat PCI rate in patients with ischemic heart failure who underwent PCI for acute myocardial infarction. 2005 by Excerpta Medica Inc.
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.